Neoleukin Therapeutics (NLTX) Announces 5M Share Proposed Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Neoleukin Therapeutics (NLTX) Prices 3.26M Share Common Offering at $15.25/Sh
July 2, 2020 9:06 AM EDTNeoleukin Therapeutics, Inc. (NASDAQ: NLTX) today announced the pricing of an underwritten public offering of 3,262,471 shares of its common stock at a price to the public of $15.25 per share. In addition, and in lieu of common stock, Neoleukin is offering to certain investors pre-funded warrants to purchase up to an aggregate of 1,737,529 shares of common stock at a purchase price of $15.249999 per pre-funded... More
